Abstract Number: 1224 • ACR Convergence 2023
Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic
Background/Purpose: Common barriers to conducting mental health (MH) screening in pediatric clinics include provider uncertainty with follow-up after screening, and concern with increasing burden of…Abstract Number: 1261 • ACR Convergence 2023
Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to comorbid anxiety and depression. From the network model perspective, comorbidity is due to direct interactions between depression…Abstract Number: 1267 • ACR Convergence 2023
Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) have become the primary treatment option for rheumatoid arthritis (RA) from 2010 in Taiwan. Tocilizumab is an interleukin-6 receptor…Abstract Number: 1264 • ACR Convergence 2023
Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study
Background/Purpose: Although telemedicine in rheumatoid arthritis (RA) could improve disease control with lower healthcare costs, knowledge of suitable parameters for self-testing disease activity still remains…Abstract Number: 1218 • ACR Convergence 2023
Discovering the Potential Application of Digital Biomarkers for Inflammatory Arthritis Patients, a Design Thinking Approach; Preliminary Results of the Patients’ Perspective
Background/Purpose: The Inflammatory Arthritis (IA) patient population is growing, whilst facing a shortage of health care professionals (HCPs). It is impossible to meet the future…Abstract Number: 1255 • ACR Convergence 2023
Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy with clinically heterogeneous presentations that can be categorized by myositis-specific antibodies (MSAs). NXP2 is among…Abstract Number: 1258 • ACR Convergence 2023
“What Is My Risk Really?”: A Qualitative Exploration and Ideal-Type Analysis of Preventive Interventions Among Individuals at Risk of Rheumatoid Arthritis
Background/Purpose: A preclinical phase of rheumatoid arthritis (RA), in which ‘at-risk’ individuals develop autoantibodies and/or symptoms and progress to clinical arthritis and classifiable RA, is…Abstract Number: 1270 • ACR Convergence 2023
Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients
Background/Purpose: Current EULAR recommendations for cardiovascular risk (CVR) assessment in rheumatoid arthritis (RA) patients indicate that the CVR evaluation should be performed according to national…Abstract Number: 1271 • ACR Convergence 2023
Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)
Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…Abstract Number: 1257 • ACR Convergence 2023
The Psychological Experience of Work for People with Inflammatory Arthritis (IA)
Background/Purpose: A large body of research reports that people with inflammatory arthritis (IA) are at increased risk for work disability, which profoundly affects all aspects…Abstract Number: 1226 • ACR Convergence 2023
Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Problems with cognitive functioning are common in childhood-onset systemic lupus erythematosus (cSLE); these may be attributed to many factors including underlying brain inflammation. Socioenvironmental…Abstract Number: 1262 • ACR Convergence 2023
“Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches
Background/Purpose: People with systemic sclerosis (SSc) often experience fatigue, which impacts daily life functioning and quality of life. We developed a 12-week, resilience-based energy management…Abstract Number: 1228 • ACR Convergence 2023
Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach
Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
- « Previous Page
- 1
- …
- 378
- 379
- 380
- 381
- 382
- …
- 2607
- Next Page »
